Understanding and Treating Female Sexual Dysfunction: An Update on Current Literature - Part 2
Media formats available:
Details
Presenters
Overview
Female sexual dysfunction (FSD) is an overall umbrella disease that may affect as many as 40 million women in the U.S., with prevalence rates cited from 30% to as high as 80%. The etiology of FSD, however, is less well-defined or understood. Comprising both physiological and psychological aspects, FSD can manifest in a variety of ways. This educational activity will include discussions on the definition, prevalence, diagnosis and related guidelines for managing this disease state.Supported through an educational grant from Valeant Pharmaceuticals North America. Learning Objectives
Upon completion of this activity, the participant should be able to: - Discuss treatment options for women with female sexual dysfunction, including the first available medication for a specific type of female sexual dysfunction
- Discuss the prevalence of female sexual dysfunction and counseling programs
- Evaluate the differences in definitions, severity criteria, and duration of disease for female sexual dysfunction as published in DSM-5
Accreditation
Accreditation Statement Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AMA Credit Designation Statement Evolve Medical Education LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Grantor Statement This continuing medical education activity is supported through an educational grant from Valeant Pharmaceuticals North America LLC.Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.Sheryl A. Kingsberg, Ph.D. Chief, Division of Behavioral Medicine Department of OB/GYN MacDonald Women’s Hospital University Hospitals Cleveland Medical Center Professor, Departments of Reproductive Biology and Psychiatry Case Western Reserve University School of Medicine Cleveland, Ohio
James A. Simon, MD, CCD, NCMP, IF, FACOG Clinical Professor Department of Ob/Gyn George Washington University Medical Director Women’s Health & Research Consultants® Washington, DC The following faculty members have the following financial relationships with commercial interests: Sheryl A. Kingsberg, Ph.D. has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: AMAG Pharmaceuticals, Inc.; Emotional Brain; Endoceuticals Inc; Palatin Technologies; and Valeant Pharmaceuticals North America LLC. Grant/Research Support: Palatin Technologies. Simon MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: AbbVie, Inc.; Allergan, Plc; AMAG Pharmaceuticals, Inc.; Amgen Inc.; Apotex, Inc.; Ascend Therapeutics; Azure Biotech, Inc.; Eisai, Inc.; JDS Therapeutics, LLC; Merck & Co., Inc; Millendo Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Novo Nordisk; Nuelle, Inc.; Perrigo Company, PLC; Radius Health, Inc.;, Regeneron Pharmaceuticals, Inc.; Roivant Sciences, Inc.; Sanofi S.A.; Sebela Pharmaceuticals, Inc.; Sermonix Pharmaceuticals, Inc.; Shionogi Inc.; Sprout Pharmaceuticals; Symbiotec Pharmalab; TherapeuticsMD; and Valeant Pharmaceuticals. Grant/Research Support: AbbVie, Inc.; Actavis, PLC; Agile Therapeutics; Bayer Healthcare LLC.; GlaxoSmithKline’ New England Research Institute, Inc.; Novo Nordisk; Palatin Technologies; Symbio Research, Inc.; and TherapeuticsMD. Patent and Trademark Holder: U.S. Patent: 4,816,257, March 28, 1989: "Method for Producing an In Vivo Environment Suitable for Human Embryo Transplant.", U.S. Trademark: Reg. No. 3,446,895, Registered June 10, 2008: “You talk…I’ll Listen. We’ll Plan Together”. U.S. Trademark: Reg. No. 3,676,269, Registered September 1, 2009: U.S. Trademark: Reg. No. 3,760,080, Registered March 16, 2010: “Women’s Health & Research Consultants & Design”, U.S. Trademark Serial No.:86-714,153. “DR. SIMON SAYS” Registered February 2, 2016. StockShareholder and/or other Financial Support: Sermonix Pharmaceuticals. Michelle Dalton, Writer and Cheryl Cavanaugh, MS, Evolve Medical Education LLC have no real or apparent conflicts of interest to report. Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Inc.; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!